A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors with KRAS G12D Mutation
INCB 161734-101
Phase 1 other active
Quick answer
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors with KRAS G12D Mutation for Advanced or metastatic solid tumors is a Phase 1 program (other) at Incyte Biosciences Distribution B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Incyte Biosciences Distribution B.V.
- Indication
- Advanced or metastatic solid tumors
- Phase
- Phase 1
- Modality
- other
- Status
- active